Advanced Cervical Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight's, "Advanced Cervical Cancer Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the Advanced Cervical Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Cervical Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

* DelveInsight's Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
* The leading companies working the Advanced Cervical Cancer Market include AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
* Promising Advanced Cervical Cancer Pipeline Therapies in the various stages of development include Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
* May 2024:- AstraZeneca- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical). This is a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT.
* May 2024:- Incyte Corporation- A Phase 1, Open-Label, Multicenter Study of INCA32459 in Participants With Select Advanced Malignancies. This is a multicenter, open-label, single-arm study to investigate the safety, tolerability, PK, pharmacodynamics and preliminary activity of INCA32459 in participants with selected advanced malignancies. Part 1 (dose escalation) will determine the recommended dose of INCA 32459 for expansion (RDE) and the maximum tolerated dose (MTD).

Request a sample and discover the recent advances in Advanced Cervical Cancer @ Advanced Cervical Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Cervical Cancer Overview

Advanced cervical cancer means the cancer has spread from the cervix to another area of the body such as the lungs. Sometimes cancer is advanced when it is first diagnosed. Unfortunately advanced cancer can't usually be cured. But treatment might control it, help symptoms, and improve your quality of life for a while. The most common places for cervical cancer to spread is to the lymph nodes, liver, lungs and bones. Treatment for advanced cervical cancer depends on the size of the cancer and where it is in the body. Chemotherapy can be used to treat advanced cervical cancer. Some women may have an operation called pelvic exenteration for cervical cancer that has come back within the pelvis.

Advanced Cervical Cancer Emerging Drugs Profile

* Imfinzi (durvalumab): AstraZeneca
* Dostarlimab: GlaxoSmithKline
* Andes 1537: Andes Biotechnologies

Learn more about Advanced Cervical Cancer in clinical trials @ Advanced Cervical Cancer Drugs [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Cervical Cancer Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Advanced Cervical Cancer. The Advanced Cervical Cancer companies which have their Advanced Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

DelveInsight's Advanced Cervical Cancer pipeline report covers around 75+ products under different phases of clinical development like

* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Advanced Cervical Cancer in development @ Advanced Cervical Cancer Clinical Trials [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.

Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

To know more about Advanced Cervical Cancer, visit @ Advanced Cervical Cancer Segmentation [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Cervical Cancer Pipeline Report

* Coverage- Global
* Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
* Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.

For further information on the Advanced Cervical Cancer Pipeline Therapeutics, reach out @ Advanced Cervical Cancer Products Development [https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced Cervical Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Cervical Cancer - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Advanced Cervical Cancer Collaboration Deals
* Late Stage Products (Phase III)
* Durvalumab: AstraZeneca
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Dostarlimab: GlaxoSmithKline
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Andes 1537: Andes Biotechnologies
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Cervical Cancer Key Companies
* Advanced Cervical Cancer Key Products
* Advanced Cervical Cancer- Unmet Needs
* Advanced Cervical Cancer- Market Drivers and Barriers
* Advanced Cervical Cancer- Future Perspectives and Conclusion
* Advanced Cervical Cancer Analyst Views
* Advanced Cervical Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-cervical-cancer-pipeline-fda-approvals-unmet-needs-preclinical-and-discovery-stage-product-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.